Savolitinib, an oral TKI against c-MET, was combined with osimertinib in patients with EGFR-mutant NSCLC with MET amplifications/mutations after progression on osimertinib in the phase 2 trial ORCHARD [111]. The gene discussed is MET; the disease is non-small cell lung carcinoma.